ENVB — Enveric Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$1.37
+$0.00 (+0.00%)
Enveric Biosciences Inc (ENVB) is a biotechnology company listed on NASDAQ. It is led by Joseph Edward Tucker Ph.D., based in 4851 Tamiami Trail N, Naples, FL, United States, 34103, with about 5 employees. Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Naples, Florida.
Net income was -$1.9M. ENVB currently screens at market cap $3.3M.
Use this ENVB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ENVB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ENVB SEC filings page. Lician reads the product cache first so this HTML stays unique to Enveric Biosciences Inc even when a live quote feed is slow.
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Naples, Florida.
ENVB Key Statistics
Market Cap
$3.34M
Volume
384,452
Previous Close
$1.46
Day Range
$1.17 – $1.50
EPS
-$19.04
Revenue
$0.00
Net Income
-$9.57M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
5
ENVB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.57M | -$17.29M | -$18.47M | -$48.98M |
| EPS (Diluted) | -$19.04 | -$121.29 | -$13.00 | $0.00 |
Total Assets
$3.08M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$2.24M
Operating Cash Flow
-$7.73M
Free Cash Flow
$0.00
Enveric Biosciences Inc Company Information
- CEO & Director
- Joseph Edward Tucker Ph.D.
- Headquarters
- 4851 Tamiami Trail N, Naples, FL, United States, 34103
- Website
- www.enveric.com
- Phone
- 239-302-1707
- IPO / Founded
- 2015-06-24
- Sector
- Healthcare
- Industry
- Biotechnology